Last year, Gerresheimer laid important foundations for future profitable growth. The company is focussing strongly on new segments such as complete solutions for biotech drugs, innovations, more sales in fast-growing markets and investments.
„Together, we laid the foundations in 2019 to make Gerresheimer fit for the future and put the company on a clear growth path. We have actively worked on the topics of innovation, excellence, customer and employee focus and will continue to do so. We have invested a record amount in growth, capacity, process optimisation and digitalisation. Our clear goal: sustainable and profitable growth,“ commented Dietmar Siemssen, Chief Executive Officer of Gerresheimer AG.
In 2019, the largest investment programme in the company's history: 185 million euros was invested, with a focus on growth projects, capacity expansion, process optimisation and digitalisation. This included the further Expansion of inhaler production at the plant in Horsovsky Tyn in the Czech Republic, the construction of the new plants in North Macedonia and Brazil as well as the expansion of the product portfolio and the creation of additional production capacities.
Two new Plants in China and India for the production of pharmaceutical primary packaging made of plastic were inaugurated. In addition, the Innovation and technology centre for glass in North America in the course of a customer event.
In the 2019 financial year, the Syringe business very positive developed favourably. Sales revenues with pharmaceutical primary packaging made of plastic increased in South America and Asia in particular. Sales revenue from primary packaging made of glass developed well, driven in particular by the very good Demand for high-quality cosmetics packaging. In the area of cosmetics packaging, the company is increasingly focussing on Sustainable solutions, in particular through the Use of recycled glass and plastic.
Sales revenues with Injection vials, ampoules and cartridges in Europe and Asia increased significantly. In North America, sales of these products declined slightly due to lower demand from a major customer. In the Advanced Technologies division the micropump for the treatment of Parkinson's disease was successfully launched on the market. A new project for the use of the micropump for patients with heart failure was acquired and is currently being implemented.
Forecast 2020
For the financial year 2020, Gerresheimer expects revenue growth in the mid-single-digit percentage range, an adjusted EBITDA margin of around 21% and investments of around 12% of revenue.
Source: Gerresheimer
